Having trouble viewing this email? View in your browser.
 
Weekly News
10 August 2021

Dear colleagues,

Please find below the latest edition of ESCMID Weekly News.

With kind regards,
ESCMID Executive Office.

 
ESCMID Research Grants 2022: One month left to apply!

The application period for ESCMID Research Grants 2022 is only open for one more month! The deadline for submitting your applications is 10 September 2021. For this call, only projects dealing with Bacterial Infections & Diseases (incl. diagnostics, pathogenesis, antibacterial susceptibility & resistance, antibacterial stewardship, vaccines) will be accepted. For further information click here and please also see the Research Grants FAQ.

 
› Read more
 
Public Consultation Phase open for new ESCMID Guidelines

“ESCMID Guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli” is undergoing public consultation. Check here how to participate. The deadline to provide feedback and comments is 30 August 2021.

ESCMID Executive Committee Elections 2021: Get your nominations in!

At the end of 2021, elections will be held among the membership to fill three (out of eight) positions in the ESCMID Executive Committee, one representing clinical microbiology and two infectious diseases.
ESCMID would like to encourage you to propose candidates by 31 August 2021 on the ESCMID website.

Join one or more of our 32 ESCMID Study Groups!

ESCMID supports 32 Study Groups that cover a wide array of topics and specialties in the fields of clinical microbiology and infectious diseases. Joining a Study Group is free and open to all ESCMID members and opens up many research and networking opportunities. Learn more about them and join on the ESCMID website.

Efficacy and safety of discontinuing antibiotic treatment for uncomplicated RTIs.

This study aimed to determine the benefits and harms of discontinuing unnecessary antibiotic therapy for uncomplicated respiratory tract infections (RTI) when antibiotics are considered no longer necessary. It is a multicentre, open-label, randomised controlled clinical trial in primary care centres from 2017 to 2020.